Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MV-LASV
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
MV-LASV is a recombinant, live attenuated vaccine candidate developed for the prevention of Lassa fever. It utilizes a measles virus (Schwarz strain) vector engineered to express the glycoprotein complex (GPC) and nucleoprotein (NP) of Lassa virus, with a mutated exonuclease domain in NP to enhance safety. The vaccine is designed to induce immunity against Lassa virus by presenting its antigens via the established measles vaccine platform. MV-LASV has demonstrated an acceptable safety and tolerability profile in phase 1 clinical trials, with immunogenicity unaffected by pre-existing immunity to measles[2][3][5][7]. The primary indication is prophylaxis against Lassa fever infection.
- Other names
- Lassa virus vaccine
02
Targets
GPC (Lassa virus glycoprotein complex)NP (Taï Forest ebolavirus nucleoprotein)
Beyond the preview
Go deeper on MV-LASV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MV-LASV.